

John Quale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/499255/publications.pdf>

Version: 2024-02-01

37
papers

1,454
citations

516710

16
h-index

414414

32
g-index

37
all docs

37
docs citations

37
times ranked

1667
citing authors

#	ARTICLE	IF	CITATIONS
1	Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center. <i>Infection</i> , 2023, 51, 247-252.	4.7	6
2	Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1282-1285.	3.0	9
3	<i>In Vitro</i> and <i>In Vivo</i> Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Microbial Drug Resistance</i> , 2022, 28, 419-424.	2.0	3
4	The initial and lingering impact of coronavirus disease 2019 (COVID-19) on catheter-associated infections in a large healthcare system in New York City. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.5	1
5	Trends in <i>Clostridioides difficile</i> infection across a public health hospital system in New York City 2019-2021: A cautionary note. <i>American Journal of Infection Control</i> , 2022, 50, 1389-1391.	2.3	5
6	Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals. <i>Microbial Drug Resistance</i> , 2021, 27, 190-195.	2.0	14
7	Effectiveness of Fluconazole Prophylaxis in a Targeted High-Risk Group in a Surgical Intensive Care Unit. <i>Surgical Infections</i> , 2021, 22, 738-740.	1.4	1
8	Trends in Healthcare Facility-Onset <i>Clostridioides difficile</i> Infection and the Impact of Testing Schemes in an Acute Care Hospital System in New York City, 2016-2019. <i>American Journal of Infection Control</i> , 2021, 49, 1262-1266.	2.3	1
9	Trends in central-line-associated bloodstream infections and catheter-associated urinary tract infections in a large acute-care hospital system in New York City, 2016-2019. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 842-846.	1.8	4
10	Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. <i>International Journal of Infectious Diseases</i> , 2020, 101, 59-64.	3.3	12
11	Cefiderocol Resistance in <i>Acinetobacter baumannii</i> : Roles of β -Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	68
12	Activity of Cefiderocol Against <i>Enterobacterales</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> Endemic to Medical Centers in New York City. <i>Microbial Drug Resistance</i> , 2020, 26, 722-726.	2.0	40
13	Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> endemic to New York City medical centres. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2938-2942.	3.0	20
14	Activity of Meropenem with a Novel Broader-Spectrum β -Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	3
15	Fulminant and rapidly fatal hemophagocytic lymphohistiocytosis in patients with HIV infection: A report of five cases and a review. <i>International Journal of STD and AIDS</i> , 2019, 30, 1224-1228.	1.1	1
16	<i>In Vitro</i> and <i>In Vivo</i> Activity of a Novel Antisense Peptide Nucleic Acid Compound Against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Microbial Drug Resistance</i> , 2019, 25, 961-965.	2.0	12
17	In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 431-436.	3.0	31
18	Effect of Porins and <i>bla</i> _{KPC} Expression on Activity of Imipenem with Relebactam in <i>Klebsiella pneumoniae</i> : Can Antibiotic Combinations Overcome Resistance?. <i>Microbial Drug Resistance</i> , 2018, 24, 877-881.	2.0	36

#	ARTICLE	IF	CITATIONS
19	Carbapenemases in New York City: the continued decline of KPC-producing <i>Klebsiella pneumoniae</i> , but a new threat emerges. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2997-3000.	3.0	13
20	In Vitro and In Vivo Activity of Single and Dual Antimicrobial Agents Against KPC-producing <i>Klebsiella pneumoniae</i> . <i>Open Forum Infectious Diseases</i> , 2017, 4, S379-S379.	0.9	0
21	Rise and fall of KPC-producing <i>Klebsiella pneumoniae</i> in New York City. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2945-2948.	3.0	26
22	Activity of Eravacycline against Enterobacteriaceae and <i>Acinetobacter baumannii</i> , Including Multidrug-Resistant Isolates, from New York City. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1802-1805.	3.2	108
23	Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5029-5031.	3.2	163
24	Activity of Meropenem Combined with RPX7009, a Novel β -Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4856-4860.	3.2	130
25	Reduction in the prevalence of carbapenem-resistant <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> in New York City. <i>American Journal of Infection Control</i> , 2015, 43, 650-652.	2.3	11
26	253 Activity of Eravacycline Against Enterobacteriaceae and <i>Acinetobacter baumannii</i> from New York City. <i>Open Forum Infectious Diseases</i> , 2014, 1, S108-S109.	0.9	0
27	1802 Prevalence of KPC-possessing <i>Klebsiella pneumoniae</i> in New York City: Have We Turned the Corner?. <i>Open Forum Infectious Diseases</i> , 2014, 1, S63-S64.	0.9	0
28	249 Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City. <i>Open Forum Infectious Diseases</i> , 2014, 1, S107-S107.	0.9	0
29	Are community environmental surfaces near hospitals reservoirs for gram-negative nosocomial pathogens?. <i>American Journal of Infection Control</i> , 2014, 42, 346-348.	2.3	8
30	In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 527-532.	2.5	18
31	Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City. <i>Microbial Drug Resistance</i> , 2012, 18, 132-136.	2.0	37
32	Contribution of OmpK36 to carbapenem susceptibility in KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Medical Microbiology</i> , 2009, 58, 1303-1308.	1.8	107
33	Correlation of Antimicrobial Resistance with β -Lactamases, the OmpA-Like Porin, and Efflux Pumps in Clinical Isolates of <i>Acinetobacter baumannii</i> Endemic to New York City. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2999-3005.	3.2	129
34	Role of AmpD, OprF and penicillin-binding proteins in β -lactam resistance in clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2007, 56, 809-814.	1.8	26
35	Interplay of Efflux System, <i>ampC</i> , and <i>oprD</i> Expression in Carbapenem Resistance of <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1633-1641.	3.2	377
36	<i>Streptococcus pneumoniae</i> , Brooklyn, New York: Fluoroquinolone Resistance at our Doorstep. <i>Emerging Infectious Diseases</i> , 2002, 8, 594-597.	4.3	34

#	ARTICLE	IF	CITATIONS
37	Carbapenem Resistance in <i>Klebsiella pneumoniae</i> and Other Members of the Family <i>Enterobacteriaceae</i> , 0, , 181-197.		0